BioInsights - Viral vector bioprocessing - spotlight

CELL & GENE THERAPY INSIGHTS

Viral vector bioprocessing

Anindya Dasgupta

Guest Editor:

Anindya Dasgupta, Director, Vector Development at Expression Therapeutics

April 2021

Download full spotlight

Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide

22 August 2021

Infographic

Read more
Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

H PhD,

P MD,

M PhD

4 August 2021

Innovator Insight

Read more
Cell and gene manufacturing: a case study approach to overcoming challenges

S Werner

29 April 2021

FastFacts

Read more
The EuLV system: lentiviral vector production based on stable producer cell lines

R Liu

21 April 2021

FastFacts

Read more
Scalable, single-use technologies for purification of lentiviral vectors

T Sanderson

29 April 2021

FastFacts

Read more
Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Mats Lundgren, Customer Applications Director, Life Sciences, Cytiva

Peter Guterstam, Product Manager, Next Generation Resins & Technologies, Cytiva

Henrik Ihre, Director Strategic Technologies, Cytiva

18 May 2021

Webinar

Watch now
Simplifying AAV protein analytics with Maurice

C Heger, PhD

28 April 2021

FastFacts

Read more
Current and future perspectives on lentiviral vector bioprocess and bioanalytical tools

P Carter

4 May 2021

Interview

Read more
The Corning^® Ascent^™ Fixed Bed Reactor (FBR) System: Designed for high yield, scalable viral vector production & other applications for cell & gene therapies.

Z Melkoumian

29 April 2021

FastFacts

Read more
Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

A Tustian

29 April 2021

Commentary

Read more
How fixed bed bioreactors are changing the game for adherent cell culture-based vector production

T Upton,

V Goral

29 April 2021

Interview

Read more
Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

D Knop

29 April 2021

Commentary

Read more
Keys to success for in-house lentiviral vector tech transfer and manufacture

N Nuñez,

L Powers

29 April 2021

Interview

Read more
Improving AAV vector manufacture: a question of scale

S Wissing,

J Coronel,

J Wölfel et al.

29 April 2021

Interview

Read more
Facilitating gene therapy development with solutions to four capsid analytical challenges

S Darling

29 April 2021

Innovator Insight

Read more
Gammaretroviral and lentiviral vector manufacture: brief overview

R Sengupta

29 April 2021

Expert Insight

Read more
Improving AAV vector manufacture: a question of scale

S Wissing,

J Coronel,

J Wölfel et al.

29 April 2021

Podcast

Listen now
Efficient and scalable purification of mRNA using affinity chromatography

Z Gulyas

28 April 2021

FastFacts

Read more
Key considerations for maximizing LV and AAV production in transient transfection workflows

Leisha Kopp, Applications Scientist, Mirus Bio

Dr. Beth Larimore, Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc

Anindya Dasgupta, Director of Vector Development, Expression Therapeutics

Nolan Sutherland, Scientist, Bluebird Bio

9 June 2021

Webinar

Watch now
Scalable suspension LVV production platforms for cell and gene therapy

Suparna Sanyal, Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec

Michael Haller, Senior R&D Scientist, Viral Vector Process Development, Lonza Pharma & Biotec

Young Shin, R&D Principal Scientist, Cell & Gene Technologies, Lonza Pharma & Biotec

13 April 2021

Webinar

Watch now